WallStSmart
AKTS

Aktis Oncology, Inc. Common stock

NASDAQ: AKTS · HEALTHCARE · BIOTECHNOLOGY

$18.75
+0.16% today

Updated 2026-04-30

Market cap
$1.18B
P/E ratio
P/S ratio
180.88x
EPS (TTM)
$-1.21
Dividend yield
52W range
$15 – $29
Volume
0.4M

Aktis Oncology, Inc. Common stock (AKTS) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20142015201720182019202020212022202320242025
Revenue$254834.00$16964.00$1.21M$1.44M$1.79M$15.35M$0.00$27.12M$1.49M$6.50M
Revenue growth (YoY)-93.3%+7020.2%+19.5%+24.0%+757.5%-100.0%-94.5%+336.9%
Cost of revenue$28749.00$110084.00$1.02M$1.01M$2.41M$19.49M$30.24M$28.07M
Gross profit$226085.00$-93120.00$188375.00$430000.00$-624000.00$-4.14M$-3.12M$1.49M$6.50M
Gross margin88.7%-548.9%15.6%29.8%-34.9%-27.0%-11.5%100.0%100.0%
R&D$470987.00$1.76M$4.43M$13.27M$19.25M$20.52M$35.71M$14.30M$25.92M$40.95M$67.45M
SG&A$920031.00$2.94M$6.02M$8.80M$8.70M$10.89M$20.71M$5.11M$7.68M$11.31M$12.60M
Operating income$-1.39M$-4.69M$-9.96M$-22.28M$-27.52M$-32.04M$-60.55M$-19.76M$-34.79M$-52.05M$-74.68M
Operating margin-1842.0%-58704.1%-1844.4%-1906.9%-1789.8%-394.5%-128.3%-3500.3%-1149.5%
EBITDA$-629596.00$-3.87M$-10.57M$-20.62M$-25.07M$-28.96M$-52.83M$-19.32M$-33.60M$-50.48M$-72.36M
EBITDA margin-1518.6%-62329.0%-1707.1%-1737.4%-1617.8%-344.1%-123.9%-3394.4%-1113.7%
EBIT$-639236.00$-3.90M$-10.68M$-21.88M$-27.57M$-32.15M$-60.95M$-19.76M$-34.79M$-52.05M$-74.68M
Interest expense$329422.00$2.89M$4.57M$77000.00$2.32M$2.66M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-1.22M$-5.41M$-9.11M$-21.74M$-30.88M$-40.87M$-59.19M$-17.93M$-28.64M$-43.98M$-63.73M
Net income growth (YoY)-342.5%-68.5%-138.7%-42.0%-32.3%-44.8%+69.7%-59.7%-53.6%-44.9%
Profit margin-2121.4%-53691.6%-1799.8%-2139.9%-2283.1%-385.6%-105.6%-2957.6%-980.9%